It’s the newest breakthrough in regenerative medicine: Using cytokine, growth factors and intracellular miRNA signaling with bio-scaffold from the extra cellular matrix components utilizing minimally-manipulated placental tissue materials. It is NOT about cell counts. It is about increasing the amplitude of signaling from the initial and continued inflammatory (injury) to the individual cell signaling pathway utilized to repair or regenerate the cellular structure that has been injured, diseased, or traumatized.
The RICHGEN components in its flowable allografts provide maximum signaling.
Yes, not quantity but quality. You can now have a vast arsenal of signaling factors to create the environment for enhanced healing that is unprecedented. Additional benefits are patient comfort, time savings and the reduced risk of liability issues due to the well documented safety profile of these allografts.
Umbilical cord blood products have multipotent cells, but many also have red blood cells and other cells with HLA type markers, adding to the risk of graft host reaction.
Adipose and bone marrow derived stem cells provide aged, low quality, and homologous adult cells that lack the rich signaling of combined pluripotent, multi-component placental allografts. Therefore, carefully combined, ethically-derived, single donor, Wharton’s jelly, placenta, amnion membrane, and amniotic fluid provide unparalleled messaging for regenerative potential and can be used for an extremely wide variety of pathologies.
RICHGEN cellular signaling components
Have you heard of RICHGEN cellular signaling components? They contain the full range and appropriate combinations for maximum signaling and healing. The extracellular and intracellular messaging from the RICHGEN growth factors BMP 4, 5 and 7 enhances bone growth. The alpha2 macroglobulin enhances anti-inflammatory activity in the joints. The collagen substrates I, III, IV, V and VI, fibronectin and laminin enhance wound healing.
The MSCs have an immunomodulating effect on the macrophages. The placental allograft components drive development of fully functional cellular repair and regeneration, whereas bone marrow aspirate cells tend to lend themselves to marginally functional cellular development.
RICHGEN cellular components have an immuno-modulatory effect and a trophic effect. In addition, RICHGEN products are never centrifuged. Nor are they combined with millions of lecithin that can artificially increase cell counts. RICHGEN is a pure product, carefully prepared for maximum effect and safety.
Anti-inflammatory action appears to require contact with the various growth factor and cytokines in suspension. The mechanism by which RICHGEN components exert their anti-inflammatory actions additionally play a role in modulating M1 and M2 macrophages. Amniotic fluid has been identified as an untapped source of cells with broad potential, which possess components that provide immunomodulatory properties. The amniotic fluid provides a stem cell niche role for the amniotic fluid. Wharton’s jelly extra cellular matrix (ECM) binds with insulin-like growth factor I (IGF-1), fibroblast growth factor (FGF), epidermal (EGF), platelet-derived (PDGF) and transforming growth factor beta (TGF-beta) providing very high stimulation to produce large amounts of aminoglycans and collagen.
RICHGEN flowable allografts’ bioactive proteins, combined with the presence of the extracellular matrix, lamin, and fibronectin, present added functional allograft that has been shown in various studies to be effective in a wide array of applications. These include:
- Topical wound healing
- Rapid response use in orthopedic pathologies, organ system pathologies, pain / anti-inflammatory control
- Scar management by following the inflammatory chemotactic pathways
- Providing components, immunomodulation, and scaffolding for significant healthy tissue generation and repair of injured tissue.
It is clear that the proprietary processing used for RICHGEN combination products creates maximum signaling for maximum regeneration potential, setting them ahead of single component regenerative grafts. The additional breakthrough proprietary biotechnology only freezes the outer membrane of the cells. The inside of the cells remains intact and unfrozen. The result: The thawed potency of RICHGEN cells is the most advanced.
RICHGEN placental allografts have been shown to be:
- Anti-inflammatory (IL-1RA, IDO, IL-10)
- Anti-microbial (Defensins, N-GAL, LL-37)
- Can be used without limitation unlike cortisone type products
- No HLA antigen and no host v graft reaction
These placental allografts also include:
- Full spectrum of growth factor proteins
- Collagen substrates
- Hyaluronic Acid
- Associated exosomes
- Pluripotent PMSCs (medicinal signaling cells)
- Fibroblasts (bFEF, PDGF) – demis regeneration
- Endothelial (VEGF, bFGF) – vascularization
- Host stem cells (SDF-1, IGF-1, epithelial, endothelial, neural) – Regulate MMPs/TIMPs
Placental allografts have an unbeatable safety record, making RICHGEN products a reliable option. No adverse events have been reported during its years of research, development and use. The allografts products are tested extensively for bioburden, including endotoxin, viruses, fungus, yeasts; tested under quality protocols and review.
Finally, RICHGEN is compliant and regulated as a human cellular or tissue-based product (HCT/P) under 21 CFG Part 1271 and Section 361 of the Public Health Service Act, FDA and ISO 13485 and cGMP guidelines.